Please login to the form below

Access and elimination: the future of DAAs in hepatitis C

Published in Pharmaphorum January 2017

The dramatic improvements in safety, efficacy, tolerability and convenience from the first wave of direct-acting antivirals (DAAs) have made a substantial contribution to changing both the treatment paradigm and the long-term prognosis for hepatitis C. 

The arrival of interferon-free, orally administered direct-acting antivirals (DAAs) in 2014 was a leap forward for the treatment of hepatitis C (HCV), a disease responsible for some 700,000 deaths globally each year.

http://www.researchpartnership.com/news/2017/01/access-and-elimination-the-future-of-daas-in-hepatit...



25th January 2017

Share

Tags

Company Details

Research Partnership

+44 (0)20 8069 5000

Contact Website

Address:
Chester House
Fulham Green
81-83 Fulham High Street
London
SW6 3JW
United Kingdom

Latest content on this profile

RP Investigates - Virtual Q&A session:
Living with Lupus
Research Partnership
Webcast:
Demand assessment
Research Partnership
White paper:
Are we prepared for the influx of CAR-Ts?
Research Partnership
New syndicated patient report -
Living with Lupus US
Research Partnership
Video:
Emotion AI
Research Partnership
Report:
Mexico’s drug market access landscape shake-up: What does it mean for pharma?
Research Partnership